Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BMRN

BMRN - BioMarin Pharmaceutical Inc Stock Price, Fair Value and News

$56.70-0.15 (-0.26%)
Market Closed

70/100

BMRN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

70/100

BMRN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$68.24

Target 3M

$59.02

Target 6M

$61.94

BMRN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BMRN Price Action

Last 7 days

-0.1%

Last 30 days

-5.6%

Last 90 days

9.2%

Trailing 12 Months

-10.4%

BMRN RSI Chart

BMRN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BMRN Valuation

Market Cap

10.9B

Price/Earnings (Trailing)

20.93

Price/Sales (Trailing)

3.52

EV/EBITDA

13.39

Price/Free Cashflow

13.09

BMRN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$68.24

Target 3M

$59.02

Target 6M

$61.94

BMRN Fundamentals

BMRN Revenue

Revenue (TTM)

3.1B

Rev. Growth (Yr)

4.08%

Rev. Growth (Qtr)

-5.97%

BMRN Earnings

Earnings (TTM)

520.4M

Earnings Growth (Yr)

-128.98%

Earnings Growth (Qtr)

-112.78%

BMRN Profitability

Operating Margin

81.32%

EBT Margin

21.95%

Return on Equity

8.59%

Return on Assets

6.83%

Free Cashflow Yield

7.64%

BMRN Investor Care

Shares Dilution (1Y)

0.80%

Diluted EPS (TTM)

2.67

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20253.0B3.1B3.1B0
20242.5B2.6B2.8B2.9B
20232.2B2.2B2.3B2.4B
20221.9B1.9B2.0B2.1B
20211.8B1.9B1.8B1.8B
20201.8B1.8B1.9B1.9B
20191.5B1.5B1.6B1.7B
20181.4B1.4B1.5B1.5B
20171.2B1.2B1.3B1.3B
2016923.7M973.7M1.0B1.1B
2015801.0M859.3M891.7M889.9M
2014572.1M627.1M666.8M749.6M
2013512.0M524.8M533.5M548.5M
2012448.6M461.9M476.6M500.7M
2011400.8M419.5M435.1M441.4M
2010000376.3M
Get all data in R, Python etc through our Historical Stock Data APIs

About BioMarin Pharmaceutical Inc

BMRN
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
 CEO
 WEBSITEbiomarin.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES3082

BioMarin Pharmaceutical Inc Frequently Asked Questions

BMRN is the stock ticker symbol of BioMarin Pharmaceutical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of BioMarin Pharmaceutical Inc is 10.89 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BMRN's fair value in chart for subscribers.

The fair value guage provides a quick view whether BMRN is over valued or under valued. Whether BioMarin Pharmaceutical Inc is cheap or expensive depends on the assumptions which impact BioMarin Pharmaceutical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BMRN.

As of Wed Jan 28 2026, BMRN's PE ratio (Price to Earnings) is 20.93 and Price to Sales (PS) ratio is 3.52. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BMRN PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, BioMarin Pharmaceutical Inc has provided -0.026 (multiply by 100 for percentage) rate of return.